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ABCB1 (Pgp, P-glycoprotein) and ABCG2 (BCRP, breast cancer resistance 
protein) are members of a transmembrane efflux ATP dependent transporter family, 
so called ATP-binding cassettes (ABC). Physiologicaly they are expressed in the 
cellular membrane and protect body tissues against potentially toxic xenobiotics 
including drugs. They represent also one of the tumor defense mechanisms when 
being able to efflux a wide variety of cytotoxic drugs out of the cancer cells leading to 
treatment failure. 
BRAF protein plays an important regulatory and signal role in MAPK/ERK 
pathway affecting cell division, differentiation and secretion. Mutations of BRAF lead 
to overactivity in MAPK/ERK pathway in many cancer cells and can be therefore 
targeted by anticancer therapy. Cobimetinib and dabrafenib are relatively new 
anticancer therapeutics inhibiting the signal pathway mentioned above and they are 
used in treatment of melanoma carrying the BRAF mutation. 
The aims of this project were to investigate whether the kinase inhibitors 
cobimetinib and dabrafenib could inhibit the efflux transporters ABCB1 and ABCG2 
and reverse drug resistance to ABCB1 and ABCG2 substrates in vitro. Using the 
Hoechst accumulation assay we studied the inhibitory effect of these drugs to MDCKII 
cell lines overexpressing ABCB1 and ABCG2 transporters. The XTT assay was further 
used to study the antiproliferative effect of cobimetinib and dabrafenib and their impact 
on cytotoxicity of daunorubicin and mitoxantron, the model anticancer substrates of 
ABCB1 and ABCG2, respectively. 
We found that cobimetinib and dabrafenib are able to significantly inhibit ABCB1 
and ABCG2 efflux transporters in MDCKII-ABCB1 and MDCKII-ABCG2 cell lines with 
cobimetinib showing higher inhibitory effect on ABCB1, compared to ABCG2. Contrary 
to cobimetinib, dabrafenib revealed preferential inhibition of ABCG2. 
Both drugs cobimetinib and dabrafenib can significantly reverse daunorubicin 
resistance in MDCKII-ABCB1 cells. Moreover, dabrafenib is able to reverse resistance 
of mitoxantrone in MDCKII-ABCG2 cells. We also showed that the presence of neither 
ABCB1, nor ABCG2 affected resistance of cobimetinib in MDCKII-ABCB1 and 
MDCKII-ABCG2 cells, indicating that these transporters do not play a role in the cellular 
resistance to these drugs. The sensitivity to dabrafenib (in tested concentrations to 50 
µM) was minimal in all the cell lines we used regardless of presence of ABCB1 or 
ABCG2.  
We demonstrate both anticancer agents, cobimetinib and dabrafenib, as 
inhibitors of ABCB1 and ABCG2 able to reverse ABC transporter-mediated drug 
resistance to daunorubicin and mitoxantron. These results may be taken into account 
when optimizing the cobimetinib- and dabrafenib- containing therapeutic regimens for 
the treatment of multidrug resistance melanoma patients. 
